Ono and Medarex Enter into Second Antibody Development Collaboration
News Mar 30, 2006
Ono Pharmaceutical Co., Ltd. and Medarex, Inc. have announced that they have entered into a collaborative agreement to research and develop a fully human anti-SDF-1 antibody for the potential treatment of multiple indications.
This is the second antibody development collaboration between Ono and Medarex. Anti-SDF-1 antibodies have been raised utilizing Medarex's UltiMAb Human Antibody Development System®.
Under this collaboration, Ono and Medarex expect to jointly work toward potential commercialization of a fully human antibody.
The two companies plan to share the costs and responsibilities of research and product development up to the completion of a Phase II clinical study.
Thereafter, each company will be fully responsible for any continued development and any commercialization in its exclusive territory; Medarex's exclusive territory is North America, and Ono's exclusive territory is all areas outside of North America.
"We are pleased to work with Ono as we continue to develop MDX-1106, our anti-PD1 antibody product candidate, and now for the development of a potential anti-SDF-1 antibody product candidate," said Dr. Donald L. Drakeman, President and CEO of Medarex.
Antitumor Immune Function in Liver Controlled by Gut MicrobiomeNews
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them.READ MORE
You Are What Your Mother EatsNews
While many factors, such as the age of the mother, overall health and genetics ultimately play a role, the correlation between a mother’s nutrition habits and metabolism has been proved to directly impact the growth of her child. And researchers believe they may be one step closer to knowing why.READ MORE